New hope for lung transplant patients: drug may block dangerous virus

NCT ID NCT05041426

Completed Prevention Sponsor: Fernanda P Silveira, MD, MS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug letermovir to prevent CMV infection in 15 adults who had a lung transplant for idiopathic pulmonary fibrosis (IPF). Participants took letermovir daily for 6 or 12 months depending on their CMV risk. The goal was to see if the drug could prevent CMV infection during and shortly after treatment. This was a small pilot study with no comparison group, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Letermovir (also known as Prevymis)
What this could lead to: If it works, this could offer a safer way to prevent CMV infection after lung transplant, reducing side effects like low white blood cell counts.
What could go wrong: This is a small pilot study with only 15 participants and no control group, so results may not apply broadly. The drug may still cause side effects or fail to prevent CMV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection idiopathic pulmonary fibrosis human betaherpesvirus 5 infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CMV LUNG TRANSPLANT

Contacts and locations

Locations

UPMC

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.